WINNIPEG, Feb. 19 /CNW/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company")
today announced a five-year research initiative to focus on the development
and commercialization of MR-guided radiation therapy and interventional
procedures, working with the University Health Network (UHN) in Toronto.
The collaboration signals the entry of IMRIS into the field of image
guided radiation therapy, expanding on its existing expertise in neurosurgery.
IMRIS, a market leader in the field of advanced surgical MR imaging and UHN,
with its specialized knowledge in imaging and radiation therapy, will focus on
the creation of innovative technologies for radiation therapy. The clinical
setting for research and testing of technologies will be Princess Margaret
Hospital (PMH), UHN's world-leading cancer research hospital. The IMRIS 3T
movable MR will be installed at PMH to enable the development of new
approaches to radiation therapy using active MR guidance.
The goals of the collaboration include the development of new
technologies, the establishment of clinical workflows and the validation of
the benefits of MR guided radiation therapy technology to both the patient and
the health system. Planned applications include the integration of the IMRIS
technology with external beam radiation therapy, MR guided biopsies and
brachytherapy of the prostate.
Dr. David Jaffray, Head of Radiation Physics at PMH, said: "MR is a
powerful, non-invasive imaging modality that enables us to better target
disease and avoid healthy tissues. This is the future of cancer treatment and
we're hoping that working with IMRIS will take us there faster."
"We are extremely pleased to be working with a recognized leader in
cancer treatment and research," said David Graves President and CEO of IMRIS.
"This co-development agreement represents a tremendous opportunity and opens
an entirely new application for the existing IMRIS platform used in
About Princess Margaret Hospital:
Princess Margaret Hospital has achieved an international reputation as a
global leader in the fight against cancer and is considered one of the top
comprehensive cancer treatment and research centres in the world. Located in
Toronto, Canada, PMH is the only facility in Canada devoted exclusively to
cancer research, treatment and education.
IMRIS (TSX: IM) is a global leader in providing fully integrated,
advanced surgical imaging solutions. The company's flagship product,
IMRISneuro, utilizes patented technology that allows a high field MRI scanner
to be moved in to the operating room on demand, providing imaging during the
surgical procedure without compromising patient safety. This unique and
innovative system has been validated by leading surgeons for use in
world-class neuroscience centers.
For more information, visit www.imris.com
For further information: Brad Woods, Investor Relations, IMRIS Inc.,
Tel: (204) 480-7094, Email: firstname.lastname@example.org